CAPTURE Inflammatory Bowel Disease (IBD) is a multi-center, longitudinal study designed with the goal of advancing precision medicine in pediatric IBD. Participants in CAPTURE IBD will continue to receive their usual care at the Children's Hospital of Philadelphia. The study team will ask participants to give blood, stool, and tissue samples at the same time as scheduled IBD clinical visits, endoscopy, or bowel surgery visits. Additionally, participants will be asked to complete electronic surveys at scheduled clinic visits, including any scheduled endoscopy or bowel surgery visits. The study will use the biospecimens and health data as a research resource that can help scientists to answer questions like:

• Can we help guide the selection of the most effective IBD therapies for pediatric and young adult populations?
• Can we help identify new treatments for pediatric patients who are not responding to current available therapies?
• Can we advance our understanding of who are the best candidates for surgery in pediatric Crohn's disease and the best treatment approaches after surgery?

CAPTURE IBD will enroll 3,000 patients, ages 4-21 years old, who have an established or suspected diagnosis of IBD at 12 sites across the United States.

This study seeks to characterize dietary intake in children with IBS and explore severity of symptoms and quality of life. This study uses the G-Tech wireless patch system to define patterns of gut motility in patients with IBS and associate these patterns with dietary intake and GI symptoms. Participants will wear the patches for 7 days as a part of the study. They can be worn under clothing and participants can continue daily activities other than swimming, bathing (although they can shower), and exercising. Stool and urine samples will also be collected to explore the gut microbiome and its association with IBS symptoms, diet, and patterns of gut motility.

We are looking to partner with patients with a confirmed diagnosis of IBS between 8 and 18 years of age who are undergoing dietary modifications such as a low-FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diet.

The study aims to understand which genes cause IBD and expand on what is known about how IBD affects those with African ancestry.

Patients are being recruited within the first two years of diagnosis at their scheduled infusion visits.

Participation in the study will last up to five years and includes an annual collection of blood, stool, and biopsy samples, and a one-time saliva sample at the first visit.

All study visits will align with clinically indicated visits already scheduled, and biopsy collection will only occur at scopes that are part of the patient's clinical care.

This study is being done in collaboration with hospitals around the country, and is headed by Emory University in Atlanta, Georgia. Participants will be compensated for their time and effort, upon completion of each visit.

The purpose of this study is to help understand how well new IBD medications work, obtain safety information, and understand patient's quality of life while on the medications.